research use only
Cat.No.S4134
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | Formula | (C3H7N.C3H5ClO)x.xCH2O3 |
Storage (From the date of receipt) | ||
|---|---|---|---|---|---|
| CAS No. | 845273-93-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C=CCN.C1C(O1)CCl.C(=O)(O)O | ||
| In vitro |
Sevelamer carbonate is designed as an alternative to sevelamer hydrochloride with enhanced buffering capacity. The sevelamer moiety consists of a carbon backbone with multiple amine groups, each separated from the backbone by a single carbon atom. In the intestine, Sevelamer carbonate become protonated and subsequently bind to dietary phosphorus molecules via ionic and hydrogen interactions. The result of these interactions is a decrease in phosphorus levels within the gastrointestinal tract, resulting in decreased dietary phosphorus absorption and decreased serum phosphorus levels. In addition to the effect on phosphorus levels, the polymeric amine structure of sevelamer has been shown to bind bile acids to reduces total cholesterol levels.
|
|---|---|
| In vivo |
Sevelamer Carbonate is able to reduce renal failure triggered inflammation and induced endotoxemia in experimental model of chronic kidney disease. Sevelamer carbonate also shows beneficial effects on renal dysfunction, secondary hyperparathyroidism and vascular calcification in rats fed with high-phosphorus diet.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01220843 | Completed | Chronic Renal Failure |
Centre Hospitalier Universitaire Amiens|Genzyme a Sanofi Company |
October 2010 | Phase 3 |
| NCT01191762 | Completed | Hyperparathyroidism|Chronic Kidney Disease |
Kenneth R. Phelps M.D.|Genzyme a Sanofi Company|Phelps Kenneth R. M.D. |
April 2010 | Phase 3 |
| NCT01011699 | Terminated | Chronic Renal Failure|Hemodialysis |
Centre Hospitalier Universitaire Amiens |
January 2010 | Phase 3 |
| NCT00853242 | Completed | Kidney Failure Chronic |
Genzyme a Sanofi Company|Sanofi |
February 2009 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.